European Journal of Heart Failure最新文献

{"title":"End-organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure-2 (RELAX-AHF-2)","authors":"Adriaan A. Voors, Marco Metra, Douwe Postmus, Barry H. Greenberg, Gadi Cotter, Beth A. Davison, Iris E. Beldhuis, G. Michael Felker, Gerasimos Filippatos, Peter S. Pang, Piotr Ponikowski, Claudio Gimpelewicz, John R. Teerlink","doi":"10.1002/ejhf.3551","DOIUrl":"https://doi.org/10.1002/ejhf.3551","url":null,"abstract":"Serelaxin is recombinant human relaxin-2, a hormone responsible for haemodynamic adaptations and organ protection in pregnancy. In the RELAX-AHF trial, serelaxin demonstrated reductions in cardiac, renal and hepatic damage. In RELAX-AHF-2, organ damage-related biomarkers were assessed in a biomarker substudy.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"7 20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142810070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of acute decompensated valvular heart disease","authors":"Enzo Lüsebrink, Hugo Lanz, Antonia Kellnar, Nicole Karam, Samir Kapadia, Raj Makkar, William T. Abraham, Azeem Latib, Martin Leon, Anna Sannino, Mony Shuvy, Mayra Guerrero, Neil Fam, Javed Butler, Marianna Adamo, Volker Rudolph, Gilbert H.L. Tang, Thomas J. Stocker, Karl-Philipp Rommel, Philipp Lurz, Holger Thiele, Steffen Massberg, Fabien Praz, Bernard Prendergast, Jörg Hausleiter","doi":"10.1002/ejhf.3549","DOIUrl":"https://doi.org/10.1002/ejhf.3549","url":null,"abstract":"Worldwide, valvular heart disease (VHD) is a common cause of hospitalization for acute heart failure. In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. Current evidence remains scarce and recommendations regarding the management of acute heart failure caused by VHD are lacking in most recent international guidelines. Herein, we review the management of acute heart failure caused by VHD with a focus on transcatheter therapies and describe currently available evidence based on a systematic literature search on the following valve pathologies: (i) aortic stenosis, (ii) aortic regurgitation, (iii) mitral regurgitation, and (iv) mitral stenosis. Articles reporting outcomes following urgent or emergent valve intervention in the setting of cardiogenic shock or acute heart failure were considered. After screening a total of 2234 articles, 76 published between 1994 and 2023 were included in subsequent analysis. Based on available evidence, proposed treatment algorithms to guide optimal management of acute heart failure caused by VHD were created. As the number of patients presenting with acute heart failure caused by VHD continues to rise and outcomes following transcatheter valve interventions continue to improve, it is inevitable that minimally invasive options will play an increasingly important role in the acute setting, especially given these patients are at an increased operative risk. This review aims to present an organized approach to the complex management and interventional treatment of patients with acute heart failure caused by VHD.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"1 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142810072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailored therapies for patients affected by systemic sclerosis with primary heart involvement: The role of rituximab","authors":"Daniela Tomasoni, Enrico Ammirati, Marco Metra","doi":"10.1002/ejhf.3543","DOIUrl":"https://doi.org/10.1002/ejhf.3543","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"21 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142804779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction","authors":"Luca Monzo, Emmanuel Bresso, Kenneth Dickstein, Bertram Pitt, John G.F. Cleland, Stefan D. Anker, Carolyn S.P. Lam, Mandeep R. Mehra, Dirk J. van Veldhuisen, Barry Greenberg, Faiez Zannad, Nicolas Girerd","doi":"10.1002/ejhf.3547","DOIUrl":"https://doi.org/10.1002/ejhf.3547","url":null,"abstract":"Patients experiencing ischaemic heart failure with reduced ejection fraction (HFrEF) represent a diverse group. We hypothesize that machine learning clustering can help separate distinctive patient phenotypes, paving the way for personalized management.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"19 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term rate of heart failure in patients with autoimmune disease: A nationwide cohort study","authors":"Guoli Sun, Emil L. Fosbøl, Mikkel Faurschou, Morten Schou, Christian Torp-Pedersen, Lars Køber, Jawad H. Butt","doi":"10.1002/ejhf.3541","DOIUrl":"https://doi.org/10.1002/ejhf.3541","url":null,"abstract":"Although certain autoimmune diseases (AIDs) have been associated with an increased rate of heart failure (HF), data on the long-term rate of HF across the spectrum of AIDs are lacking. We investigated the long-term rate of HF in individuals with a history of 28 different AIDs.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142797759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endomyocardial biopsy in the diagnosis of cardiac sarcoidosis","authors":"Henriikka Mälkönen, Jukka Lehtonen, Pauli Pöyhönen, Valtteri Uusitalo, Mikko I. Mäyränpää, Markku Kupari","doi":"10.1002/ejhf.3545","DOIUrl":"https://doi.org/10.1002/ejhf.3545","url":null,"abstract":"AimsWe set out to assess the utility of endomyocardial biopsy (EMB) in cardiac sarcoidosis (CS). Historically, EMB sensitivity in CS is only ≤25%, but comprehensive analyses of its current diagnostic performance are not available.Methods and resultsThe data of 260 consecutive patients with <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> (mean age 49 years, 60% female) meeting the Heart Rhythm Society diagnostic criteria were analysed retrospectively. Overall, 216 patients (83%) had undergone <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content>, 47 with repeat procedures. <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> overall sensitivity was 38%, rising to 49% after repeat biopsies. On logistic regression analysis, positive <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> was predicted independently by presentation with ventricular tachyarrhythmia with an odds ratio (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content>) of 3.8 (95% confidence interval [CI] 1.2–12.0, <jats:italic>p</jats:italic> = 0.021), left ventricular ejection fraction ≤45% (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 3.7, 95% CI 1.5–9.1, <jats:italic>p</jats:italic> = 0.004), elevation of cardiac troponins (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 2.7, 95% CI 1.1–6.4, <jats:italic>p</jats:italic> = 0.024), and presence of late gadolinium enhancement in left ventricular mid‐apical septal segments on magnetic resonance imaging (<jats:styled-content style=\"fixed-case\">OR</jats:styled-content> 4.1, 95% CI 1.2–13.8, <jats:italic>p</jats:italic> = 0.024). <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> sensitivity, counting in repeats, was 16% in patients (<jats:italic>n</jats:italic> = 37) without any independent predictor versus 38%, 60%, 79%, and 88% in those with 1 (<jats:italic>n</jats:italic> = 76), 2 (<jats:italic>n</jats:italic> = 62), 3 (<jats:italic>n</jats:italic> = 33), and 4/4 (<jats:italic>n</jats:italic> = 8) predictors, respectively. The rate of serious complications was 0.7% without mortality or permanent harm. Positive <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> was not an independent predictor of prognosis.ConclusionThe sensitivity of <jats:styled-content style=\"fixed-case\">EMB</jats:styled-content> in <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> depends on the extent, activity, and location of myocardial involvement, being the higher the more severe <jats:styled-content style=\"fixed-case\">CS</jats:styled-content> is. Its use should rely on weighing the pre‐test likelihood and individual value of positive biopsy against the procedural risks.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"27 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outpatient worsening of heart failure and mortality in transthyretin amyloid cardiomyopathy","authors":"Lawrence Zeldin, Joanna B.S. Eichler, Sergio L. Teruya, Ariel Y. Weinsaft, Alfonsina Mirabal, Margaret O. Cuomo, Kimberly Mateo, Stephen Helmke, Mathew S. Maurer","doi":"10.1002/ejhf.3540","DOIUrl":"https://doi.org/10.1002/ejhf.3540","url":null,"abstract":"Transthyretin cardiomyopathy (ATTR-CM) is characterized by episodes of worsening heart failure (WHF) which can include heart failure (HF) hospitalizations or urgent unplanned visits for administration of intravenous diuretics. WHF characterized by outpatient intensification of oral loop diuretics is common yet its prognostic implications for ATTR-CM patients relative to other WHF events remains unclear. We assessed how WHF characterized by outpatient diuretic intensification (ODI) relates to mortality in this population.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"79 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global burden of disease attributable to high body mass index in 204 countries and territories from 1990 to 2021 with projections to 2050: An analysis of the Global Burden of Disease Study 2021","authors":"Zenghong Wu, Fangnan Xia, Weijun Wang, Kun Zhang, Mengke Fan, Rong Lin","doi":"10.1002/ejhf.3539","DOIUrl":"https://doi.org/10.1002/ejhf.3539","url":null,"abstract":"Understanding the global burden of disease attributable to high body mass index (BMI) is essential for informing public health strategies and interventions to mitigate the impact of obesity-related conditions.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"16 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: A pilot randomized controlled trial","authors":"Neil Keshvani, Syed Rizvi, Matthew W. Segar, James W. Miller, Juan David Coellar, Kershaw V. Patel, Bethany Roehm, W.H. Wilson Tang, Ambarish Pandey","doi":"10.1002/ejhf.3537","DOIUrl":"https://doi.org/10.1002/ejhf.3537","url":null,"abstract":"Diuretic resistance (DR) in heart failure (HF) is associated with worse outcomes. Furoscix®, a self-administered subcutaneous (sc) furosemide injection administered via on-body infusor, is approved for HF congestion relief. However, its efficacy in patients with DR post-HF hospitalization remains unknown.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"69 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142758558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midterm outcomes of patients with native heart recovery after Impella 5+ for cardiogenic shock","authors":"Marta Bandini, Nicoletta D'Ettore, Walter Iannotti, Tommaso Capobianco, Giulia Maj, Astrid Cardinale, Alina Gallo, Andrea Audo, Federico Pappalardo","doi":"10.1002/ejhf.3544","DOIUrl":"https://doi.org/10.1002/ejhf.3544","url":null,"abstract":"AimsLeft ventricular unloading by percutaneous microaxial flow‐pump devices has been shown to improve survival in patients with cardiogenic shock (CS). The objective of the study is to examine whether Impella 5.0/5.5 (5+) support is effective in facilitating heart recovery, overall survival, and quality of life.Methods and resultsThis single‐centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. The primary endpoint was survival at 180 days and freedom from implantable cardioverter‐defibrillator (ICD), heart transplant/left ventricular assist device (LVAD), or readmission for heart failure. Functional status was assessed with New York Heart Association (NYHA) classification. Between June 2022 and April 2024, 20 patients with CS (64 ± 8.9 years, 80% male) received Impella 5+ and discharged with heart recovery. Before Impella placement, mean left ventricular ejection fraction (LVEF) was 19.2 ± 5.2%, 7 (35%) patients were SCAI stage C, 9 (45%) SCAI stage D, and 4 (20%) SCAI stage E, and the mean vasoactive‐inotropic score was 23.2 ± 38.0. The average duration of Impella support was 10.5 ± 8 days. At 180 days, 19 (95%) patients were alive, no patient received a heart transplant/LVAD, 40% were implanted with an ICD and there were two admissions for heart failure. The mean LVEF was 33.5 ± 10.7%, 5 (26.3%) patients were NYHA class I, 9 (47.4%) were NYHA class II, and 5 (26.3%) were NYHA class III. One patient died from a non‐cardiac cause.ConclusionImpella 5+ represents a promising treatment strategy for CS, providing high rates of sustained native heart recovery. A comprehensive platform of mechanical and pharmacological unloading is key.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"44 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142758484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}